



Reinforcing patient safety in Europe

14-15 June 2011
Zagreb, Croatia



Accession Preparation: Situation in Croatia

Siniša Tomić, PhD, Associate Professor
Head of the Agency for Medicinal Products and
Medical Devices (HALMED), Croatia


Content:



- **Croatian Agency for Medicinal Products and Medical Devices (HALMED)**
- **Role of HALMED**
- **Harmonisation of legislation with the acquis (Brief history of Croatian regulatory framework)**
- **Twinning Light Project**
- **HALMED's achievements and challenges**
- **Conference Announcements**



- ✓ **National regulatory authority**
- ✓ **Provides services pertaining to human medicinal products, medical devices and homeopathic products in accordance with the Croatian legislation**
- ✓ **Established on October 1, 2003**
- ✓ **Legal compliance is supervised by the Ministry of Health and Social Welfare**
- ✓ **Generates its own income through service fees and annual charge**



74 employees, 2003



130 employees, 2011

Collaborates with various international institutions:



...and Medicines agencies of the EU member states:



Twinning Light Project

...as well as Medicines agencies in the region:



... and last, observer to :



CO-OPERATION WITH EMA IPA Programme 2009-2011

Potential Candidate Countries

Candidate Countries

Croatia

Macedonia

Turkey

Montenegro

EMA

IPA

Albania

Bosnia and
Hercegovina

Kosovo under UNSC
Resolution 1244/99

Serbia

Legend:

EMA European Medicines Agency
IPA Instrument for Pre-Accession

HALMED'S KEY ROLE




Protecting public health by ensuring safety, quality and efficacy of medicines



Promotes public health by helping people to understand the risks and benefits of the medicines they use

Safeguard public health by carrying out its communication role through provisions of accurate, scientifically proved and timely information on medicinal products and medical devices to healthcare professionals, patients and the general public



The screenshot shows the HALMED website homepage. The header features the HALMED logo and the text 'Agency for Medicinal Products and Medical Devices of Croatia'. A large banner on the right says 'WELCOME TO THE WEBSITE OF THE AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES'. Below the header is a navigation bar with links: MEDICINAL PRODUCTS, MEDICAL DEVICES, LICENCES - MANUFACTURING AND SALE, PHARMACOVIGILANCE, and PHARMACOPOEIA. On the right side, there are links for NEWSLETTER, ENQUIRIES, MOST IMPORTANT CONTACTS, and WORKSHOPS / EVENTS. The main content area is divided into three columns. The left column contains a list of links: News, About Us, Fees, Central Ethics Committee, International Cooperation, Seminars and Workshops, Useful Links, Legislation, Publications and Reports, Forms, Approval for the Import, and Contacts. The middle column features a red-bordered box with the text 'For Patients INFORMATION ON MEDICINES' and a 'more' button. Below this is a 'NEWS' section with three items: 'Newly approved medicinal products 11.02.2011.', 'Newly approved medicinal products 11.01.2011.', and 'Newly approved medicinal products 13.12.2010.'. The right column contains a section for '15-18 September 2010' titled 'HALMED-Info-Day and a Workshop for QPs in Pharmacovigilance - "What changes did the new Ordinance bring?"'. It describes the event, which will be held on 16 September 2010 and a Workshop for a QP in Pharmacovigilance on 17-18 September 2010, within the Sixth Croatian Congress of Pharmacology with International Participation. It also mentions that the Congress will be held on 15-18 September 2010 in Opatija, in Millenium Grand Hotel 4 opatijska cvijeta, organised by the Croatian Pharmacological Society (HDF), School of Medicine of the University of Rijeka and Agency for Medicinal Products and Medical Devices (HALMED). The text continues: 'During the plenary lectures organised by the HALMED, the Head of the Agency and experts from the HALMED will present the activities within the HALMED's scope of work. The lectures will present an occasion for interactive discussion with the HALMED experts.'

New Safety Information

HALMED :: Pharmacovigilance | New Safety Information - Windows Internet Explorer

http://www.almp.hr/?ln=en&sr=farmakovigilancija&id=novi_podaci

File Edit View Favorites Tools Help

Pretvori Odaberi

Search CNN YouTube Facebook Games Celebrity Amazon Word of the Day Weather E-mail

Favorites http-www.capsugel.com-p... Meeting Portal Welcome to t... WHOCC - ATC-DDD Index Heads of Medicines Agency... Dictionary and Thesaur... Dictionary.com Find the Me... European Directorate for th... European Medicines Agency Suggested Sites Get More Add-ons Customize Links

HALMED :: Pharmacovigilance | New Safety Information



HALMED
Agency for Medicinal Products
and Medical Devices of Croatia

WELCOME TO THE WEBSITE
OF THE AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

[HOME](#) [ABOUT](#) [CONTACT](#) [NEWS](#) [PRIVACY](#)

[SEARCH](#)

[NEWSLETTER](#)

[ENQUIRIES](#)

[MOST IMPORTANT CONTACTS](#)

[MEDICINAL PRODUCTS](#) [MEDICAL DEVICES](#) [LICENCES, MANUFACTURING AND SALE](#) [PHARMACOVIGILANCE](#) [PHARMACOPOEIA](#)

[News](#)
[About Us](#)
[Fees](#)
[Central Ethics Committee](#)
[International Cooperation](#)
[Seminars and Workshops](#)
[Useful Links](#)
[Legislation](#)
[Publications and Reports](#)
[Forms](#)
[Approval for the Import](#)
[Contacts](#)

[NEW SAFETY INFORMATION](#)

Notice concerning the shorter shelf-life of Act-HIB, vaccine against Haemophilus influenzae type B, Vaccinum haemophili stirpe b coniugatum, Lot D0636-3
01.06.2010.

In collaboration with the Agency for Medicinal Products and Medical Devices, on 31 May 2010, Medoka d.o.o. sent a notice to the Croatian National Institute of Public Health, all County Institutes of Public Health, Institute of Immunology (warehousing and distribution of vaccines from the Vaccination Programme) and vaccinators, advising them of the shorter shelf life of Act-HIB, vaccine against Haemophilus influenzae type b, Lot: D0636-3. The packaging of the above vaccine lot reads Expiry Date June 2011. The Agency, when issuing the Special Quality Control Certificate, shortened the shelf life to 31.12.2010, due to a discrepancy in the respective expiry dates of the finished medicinal product and the enclosed solvent, since the enclosed solvent has an expiry date of December 2010. Consequently, the vaccine must not be used after 31.12.2010.

The text of the letter can be found below (available in Croatian):
Notice concerning the shorter shelf-life of Act-HIB, vaccine against Haemophilus influenzae type b, Lot D0636-3

OTHER NEWS

Important notice concerning safety of medicinal products containing the active substance bufexamac with recommendations for physicians, pharmacists and patients
01.06.2010.

The European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revocation of marketing authorisation for all medicinal products containing the active ingredient bufexamac. Based on the CHMP's opinion, the European Commission will issue final recommendations for the medicinal products containing the aforementioned active substance.

The Agency for Medicinal Products and Medical Devices (HALMED) initiated the review process for the EMA's recommendation, issuing the recommendations for physicians, pharmacists and patients.

Adverse Drug Reactions Report for 2009
31.05.2010.

On 31 May 2010, the Agency for Medicinal Products and Medical Devices (HALMED) posted on its website the Annual Report on Spontaneous Reporting of Adverse Drug Reactions for 2009. The Report was drafted in accordance with the Medicinal Products Act (Official Gazette Nos. 71/07 and 45/09) and the accompanying Ordinance on Pharmacovigilance (Official Gazette No. 125/09), pursuant to which HALMED monitors adverse drug reactions (ADRs) in the Republic of Croatia that are related to the marketed medicinal products and the medicinal products in clinical trials, which healthcare professionals, marketing authorisation holders and clinical trial authorisation holders have an obligation to report.

[SPC AND PIL](#)
[LATEST INFORMATION](#)
[QUESTIONNAIRE](#)
[QUALITY POLICY](#)

Dear Healthcare Professional Letter

HALMED :: Pharmacovigilance | Dear Healthcare Professionals Letters - Windows Internet Explorer

Internet Explorer address bar: <http://www.halmed.hr/7?tr=en&sw=farmakovigilancija&id=pisma>

Menu: File Edit View Favorites Tools Help

Search: Search

Navigation: CNN YouTube Facebook Games Celebrity Amazon Word of the Day Weather E-mail

Page: Page Safety Tools



Agency for Medicinal Products
and Medical Devices of Croatia

WELCOME TO THE WEBSITE
OF THE AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

[Home](#)
[Documents](#)
[Pharmaco](#)
[E-mail](#)
[HRV](#)

SEARCH

[NEWSLETTER](#)

[ENQUIRIES](#)

[MOST IMPORTANT CONTACTS](#)

[MEDICINAL PRODUCTS](#)
[MEDICAL DEVICES](#)
[LICENCES - MANUFACTURING AND SALE](#)
[PHARMACOVIGILANCE](#)
[PHARMACOPEIA](#)

[DEAR HEALTHCARE PROFESSIONALS LETTERS](#)

News

About Us

Fees

Central Ethics Committee

International Cooperation

Seminars and Workshops

Useful Links

Legislation

Publications and Reports

Forms


Approval for the Import

Contacts

Name	Date	Download
Pismo liječnicima o tiskarskoj pogrešci u Uputi priloženoj uz lijek Integrilin (eptifibatid)	07.02.2011.	GlaxoSmithKline d.o.o.
Pismo zdravstvenim djelatnicima o promjeni načina izdavanja lijekova za lokalnu primjenu koji sadrže ketoprofen	27.01.2011.	Sandoz d.o.o., Berlin-Chemie Menarini Hrvatska d.o.o.
Pismo liječnicima o novim podacima vezanim uz sigurnost primjene lijeka Multaq (dronedaron)	26.01.2011.	Sanofi-aventis Croatia d.o.o.
Pismo liječnicima o podacima vezanim uz opskrbu i sigurnost primjene Dianeal, Extraneal i Nutrineal otopina	24.01.2011.	Agmar d.o.o.
Pismo liječnicima o hepatalnim nuspojavama povezanim s primjenom lijeka Vfend (vorikonazol)	14.01.2011.	Pfizer Croatia d.o.o.
Nastavno pismo liječnicima o podacima vezanim uz sigurnost primjene Dianeal, Extraneal i Nutrineal otopina	17.12.2010.	Agmar d.o.o.
Pismo liječnicima o mogućnosti otpočinjanja liječenja novih bolesnika lijekom PegIntron®	17.12.2010.	Schering-Plough d.o.o., tvrtka kći Merck & Co., Inc.
Pismo liječnicima o novim podacima vezanim uz sigurnost primjene Dianeal, Extraneal i Nutrineal otopina za peritonejsku dijalizu	10.12.2010.	Agmar d.o.o.
Pismo liječnicima o novim podacima vezanim uz sigurnost primjene lijeka Sutent kapsule (sunitinibum) u bolesnika istovremeno ili prethodno liječenih bisfosfonatima	07.12.2010.	Pfizer Croatia d.o.o.
Pismo liječnicima o novim podacima vezanim uz sigurnost primjene lijeka RoActemep® 20 mg/ml kalcijevog acetata za infuziju	03.12.2010.	Roche d.o.o.

HARMONISATION WITH THE EU LEGISLATION

- *acquis communautaire*
- negotiation procedure between Croatia and the EU: Chapter 1 “Free Movement of Goods” which defines regulation of medicines and medical devices was closed in April 2010
- continuous monitoring and harmonisation of Croatian legislation with the aquis



HISTORY OF REGULATORY FRAMEWORK IN CROATIA

**Act on
Medicinal
Products and
Medical
Devices, 1997**

**Act on Medicinal Products
and Medical Devices, 2003**

**Medicinal Products Act
(2007/amend. 2009)**

**Medical Devices Act
(2008)**

Ordinance on monitoring
of quality defects, 2005

Ordinance
on GDP, 2005

Ordinance on Advertising
MP, HP and MD, 2005

Ordinance on Special
Conditions for EU
Authorised MP (2008)

Ordinance on GMP, 2009

Ordinance on
Advertising of MP&HP, 2009

Ordinance on
Bioequivalence,
1999

Ordinance on Drug consumption
reporting, 2005

Ordinance on
GLP, 2006


Ordinance on Quality testing, 2005

Ordinance on the Procedure
for Granting MA (2008/amend.
in 2009)

Ordinance on PHV,
2009

Ordinance on Clinical
trials and GCP, 2010

Ordinance on Marketing, labelling
and advertising of THMP, 2010



nCADREAC (Authorisation of Products Previously Authorised in the EU)

- New Collaborative Agreement between Drug Regulatory Authorities in Central and Eastern European Countries (supported by EU officials and encouraged by the WHO Regional Office for Europe)
- provisions of nCADREAC-incorporated in the Croatian legislation

CADREAC 1997 (Bulgaria, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Estonia, Poland, Romania, Slovakia, Slovenia, Turkey)

Supported also by European Union (EU) officials and encouraged by the WHO Regional Office for Europe, We, the Heads of Drug Regulatory Authorities in Central and Eastern European Countries (further on: Signatories)

During the CADREAC Annual Assembly, March 2004 in Bucharest, followed by many discussions Have agreed to sign the present Agreement in order to start a new informal collaboration.

Aim of the Collaboration Article I

- (1) To facilitate implementation of EU standards and professional obligations to drug regulations into practice.
- (2) To create a better environment and broader possibilities for Signatories outside the EU to be involved in professional activities organised by the EU.
- (3) To facilitate introduction of mutually recognisable procedures and activities relating to „Good Practices“ in accordance with EU regulatory principles for the assessment and marketing authorisation of medicinal products.
- (4) To establish a forum in which joint strategies concerning either approaching or later EU accession or working together with the EU are developed and particularities referring to the group as a whole are elaborated among Signatories and/or together with EU structures to avoid unnecessary duplication of work and save resources.
- (5) To facilitate the preparation of future drug regulatory meetings of Central and Eastern

nCADREAC 2006



Bulgaria



Croatia



Czech Republic



Hungary



Romania



Slovakia

tates.
uropean network of regulatory
i.


orities (Participating DRAs), and
ilatory authority, all the latter have the
nent.
itory authorities :
or states
a signed association agreement

have valid mutual recognition
drug regulations
astern European countries.
embers of this Agreement.
field(s) in which the mutual
with the EU.
embers of this Agreement.
plementation of any of its

recommendations is voluntary for all Participating DRAs.

(4) Without prejudice to the EU internal confidentiality rules, all Participating DRAs may have access to all the information generated within the framework of the Collaboration.

nCADREAC




Legend:

MRP/DCP MAH	Mutual Recognition or Decentralised Procedure Marketing Authorisation Holder
CP MAH	Centralised Procedure Marketing Authorisation Holder
RMS	Reference Member State
nCADREAC	New Collaboration Agreement between Drug Regulatory Authorities in Central and East European Countries

Current situation

- Fast track procedure for EU products
- MA procedure
- Data exclusivity
- Validity of MA
- Quality control (MA procedure)
- Batch to batch control of EU products
- eCTD
- Inspection and enforcement
- Parallel trade
- New Regulation on Variations
- PIP
- New PhV legislation

- ✓ Yes (nCADREAC)
- ✓ 210 days NP; CP 150 days, MRP/DCP 180 days
- ✓ 6 years (will be changed with the accession)
- ✓ 5 years
- ✓ First batch required (biologicals every batch)
- ✓ No, but CoA submitted to the Agency
- ✓ Yes
- ✓ Ministry of Health and Social Welfare
- ✗ No
- ✗ No
- ✗ No
- ✗ No *



Adverse drug reactions

Counterfeited medicines

Safety

Quality defects

Efficacy

...BUT NOT OVERREGULATE



**IPA PROGRAM 2007
TWINNING LIGHT PROJECT**

***Strengthening of expert capacity in
implementation of EU legislation on medicines in the
Croatian Agency for Medicinal Products and Medical Devices”***

December 2010 – June 2011

TWINNING LIGHT PROJECT

- **Duration of the project: 6 months**
- **30 AEMPS experts divided into 11 visits held various training seminars and workshops**
- **instructed and trained HALMED's experts to work in line with EU practice**
- **trained to implement EU directives, rules and/or procedures for specific groups of medicinal products - quality, safety and efficacy evaluation of well-established use medicines, herbal medicinal products, generics and biologicals (vaccines and sera, blood/blood products, biosimilars)**
- **overview of pharmaceutical inspection and enforcement**
- **trained to evaluate of bioequivalence data**
- **2 study visit of HALMED's experts to Spanish OMCL (on-site experience on Quality Control of biologicals)**



The European Union's IPA Programme for Croatia

**IPA PROGRAM 2007
Twinning Light Project**

**Strengthening of expert capacity in
Implementation of EU legislation
on medicines in the Croatian Agency
for Medicinal Products and
Medical Devices**



**A project was implemented by
Spanish Agency for Medicines and
Medical Devices
and
Croatian Agency for Medicinal Products and
Medical Devices**

TWINNING LIGHT PROJECT SEMINAR &WORKSHOP



eCTD

- **Introduced in Croatia on June 30, 2010**
- **welcomed to submit eCTD or NeeS**
- **national requirements – in Working documents folder**
- **if documentation is submitted in NeeS format, eventually it should be shifted to eCTD, not to paper; similarly if documentation is submitted in eCTD, it should not be shifted to NeeS or paper**
- **still mandatory to submit Module 1-3 in paper**
- **By June 2011, HALMED received:**
 - **NeeS: 4 dossiers and 32 sequences**
 - **eCTD: 39 dossiers and 384 sequences**

NEW PROJECTS IN HALMED

- **IPA TAIB 2009 - Project on eCTD – Preparation for eCTD and implementation of digital archival information system (worth 1 240 000 EUR)**
- **Expected start of implementation: September 2011**

HALMED CHALLENGES ON THE ROAD TO EU ACCESSION

Dossier upgrading

**Improving quality and consistency of the published
product information**

**Maintaining one operational regulatory framework in the
pre-accession period ...and**

**...to be ready to implement another one fully transposed
regulatory framework for the day 1 of the accession**

How to address global public health issues



HALMED : Publikacije | Izvje... vmacoli (ALMP) @ Produc... Page Safety

Display Settings vmacoli (ALMP) @

Create and Send ICSRs ICSRs Medicinal Products MedDRA

Reset Application Reset Section Clear ReRun Modify Delete Excel Export Follow Up Forward Load

Safety Reports (2) PHHY2010US18856

Report from studies - 28/05/2010 - CA-ABE

Report Duplicates (-)

Linked Reports (-)

Local Safety Report Ack

Primary Sources (2)

Sender

Receiver

Patient

ICHICSR Message

Reports in the Case

Spontaneous - 16/08/2010 - BE-002147023

Report Duplicates (-)

Linked Reports (-)

Local Safety Report Ack

Primary Sources (1)

Sender

Receiver

Patient

ICHICSR Message

Reports in the Case

ICHICSR Messages (-)

Series

Case Tracking List

Fields

Conditions (AND)

Results

Result 10. rujan 2010 15:58:39

Result 10. rujan 2010 15:59:30

Ready to Run

All Reports

Reports with Warnings

Reports with Errors

ICHICSR Messages


Tracking

Num	Local Report Number	Transmission date	Primary Source Coun...	Safety Report ID	Report Type	Case type
☐ 0001	472476	12/04/2010	Australia	AU-ABBOTT-10P-008...	Report from studies	Marketing A
☐ 0002	472519	12/04/2010	United States	US-ABBOTT-10P-163...	Report from studies	Marketing A
☐ 0003	472534	14/04/2010	Malawi	MW-ABBOTT-10P-10...	Spontaneous	Marketing A
☐ 0004	472746	27/04/2010	United Kingdom	GB-ABBOTT-10P-167...	Report from studies	Marketing A
☐ 0005	472871	14/05/2010	Sweden	SE-ABBOTT-08P-150...	Spontaneous	Marketing A
☐ 0006	472989	17/05/2010	United States	US-ABBOTT-10P-163...	Spontaneous	Marketing A
☐ 0007	473644	24/05/2010	Japan	JP-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0008	473865	26/05/2010	United Kingdom	GB-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0009	473959	27/05/2010	France	FR-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0010	473984	27/05/2010	Belgium	BE-PFIZER INC-2010...	Report from studies	Marketing A
☐ 0011	472614	19/04/2010	France	FR-ABBOTT-10P-056...	Spontaneous	Marketing A
☐ 0012	472677	22/04/2010	Germany	DE-ABBOTT-10P-062...	Spontaneous	Marketing A
☐ 0013	473331	21/05/2010	Spain	ES-PFIZER INC-2010...	Report from studies	Marketing A
☐ 0014	473459	21/05/2010	Malaysia	MY-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0015	473803	27/05/2010	Japan	JP-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0016	473983	27/05/2010	Japan	JP-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0017	472548	15/04/2010	France	FR-ABBOTT-10P-056...	Spontaneous	Marketing A
☐ 0018	472557	15/04/2010	Malawi	MW-ABBOTT-10P-10...	Spontaneous	Marketing A
☐ 0019	472567	16/04/2010	Canada	CA-ABBOTT-10P-028...	Report from studies	Marketing A
☐ 0020	472601	19/04/2010	Germany	DE-ABBOTT-10P-062...	Report from studies	Marketing A
☐ 0021	472644	21/04/2010	Netherlands	NL-ABBOTT-10P-114...	Report from studies	Marketing A
☐ 0022	472874	14/05/2010	United States	US-ABBOTT-10P-163...	Spontaneous	Marketing A
☐ 0023	473195	19/05/2010	Singapore	SG-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0024	473207	20/05/2010	Japan	JP-PFIZER INC-2009...	Report from studies	Marketing A
☐ 0025	473252	19/05/2010	France	FR-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0026	473339	20/05/2010	Italy	IT-PFIZER INC-20100...	Spontaneous	Marketing A
☐ 0027	473552	21/05/2010	United States	US-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0028	473912	27/05/2010	France	FR-ABBOTT-10P-056...	Spontaneous	Marketing A
☐ 0029	474026	27/05/2010	France	FR-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0030	472525	13/04/2010	United Kingdom	GB-ABBOTT-10P-167...	Spontaneous	Marketing A
☐ 0031	472613	19/04/2010	Japan	JP-ABBOTT-10P-087...	Report from studies	Marketing A
☐ 0032	472729	26/04/2010	Brazil	BR-ABBOTT-09P-020...	Report from studies	Marketing A
☐ 0033	473068	18/05/2010	France	FR-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0034	473158	19/05/2010	United States	US-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0035	473215	19/05/2010	Japan	JP-PFIZER INC-2010...	Spontaneous	Marketing A
☐ 0036	473257	19/05/2010	Japan	JP-PFIZER INC-2010...	Spontaneous	Marketing A

• HALMED connected to EudraVigilance gateway since April, 2010

• a submission of ADRs by 25 MAHs (1/4 of all MAH in Croatia)

**Correct and active ICSRs in the WHO global ICSR database
per million inhabitants and year
Period covers: April 2006 to March 2011**



- Afssaps and HALMED Joint Conference: Information on Medicinal Products; 29-30 September, 2011, Dubrovnik**





• WHO National Centres Meeting, 30
October -3 November, 2011
Dubrovnik

Thank you for your attention!

